Table 4.

Patients (%) in each disease activity group on DMARD monotherapy and combination therapy

	Clinical remission (N = 34)	Low disease activity (N = 42)	Moderate/high disease activity (N = 54)	Total (N = 130)
Combination therapy, n (%)	17 (50.0)	15 (35.7)	31 (57.4)	63 (48.5)
bDMARD/csDMARD	13 (38.2)	11 (26.2)	20 (37.0)	44 (33.8)
bDMARD/csDMARD/tsDMARD	1 (2.9)	0 (0.0)	0 (0.0)	1 (0.8)
csDMARD	3 (8.8)	2 (4.8)	8 (14.8)	13 (10.0)
csDMARD/tsDMARD	0 (0.0)	2 (4.8)	3 (5.6)	5 (3.8)
Monotherapy, n (%)	17 (50.0)	27 (64.3)	23 (42.6)	67 (51.5)
bDMARD	14 (41.2)	11 (26.2)	13 (24.1)	38 (29.2)
csDMARD	3 (8.8)	14 (33.3)	10 (18.5)	27 (20.8)
tsDMARD	0 (0.0)	2 (4.8)	0 (0.0)	2 (1.5)